Clinical TrialApr 17, 2026, 04:06 PM
ORIC Presents Positive Preclinical Data for Rinzimetostat in Prostate Cancer
AI Summary
ORIC Pharmaceuticals presented multiple posters at the 2026 AACR Annual Meeting, highlighting preclinical data for rinzimetostat (ORIC-944) in prostate cancer. The research indicates that PRC2 activity is a critical therapeutic target observed early and sustained throughout prostate cancer progression and resistance. Rinzimetostat, an allosteric EED inhibitor, demonstrated antitumor activity in combination with darolutamide across various prostate cancer models and showed potential advantages over EZH2 targeting, overcoming acquired resistance mechanisms seen with other inhibitors.
Key Highlights
- PRC2 activity elevated in >50% of localized primary tumors and most metastatic CSPC/CRPC.
- Rinzimetostat + darolutamide showed antitumor activity in CSPC and CRPC models.
- Rinzimetostat retained activity in EZH1-overexpressed cells, unlike mevrometostat/tazemetostat.
- Preclinical studies show rinzimetostat overcomes tazemetostat/valemetostat resistance.
- Rinzimetostat demonstrated improved solubility, oral bioavailability, and clinical half-life.
Price Impact
More from ORIC